On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration’s Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular age-related macular degeneration (nAMD). nAMD, a severe eye disease leading to blindness, is characterized by new blood vessel formation in the macula.

JWK001 is a significant advancement in AAV gene therapy, using a two-plasmid packaging system that is more efficient and cost-effective than the traditional three-plasmid approach. This innovation enhances patient accessibility and is effective for patients unresponsive to single-target treatments. JWK001 introduces an anti-VEGF protein into retinal cells, avoiding the risks associated with frequent traditional nAMD treatments. The initial patient, requiring an average of 10.18 anti-VEGF injections annually, experienced no need for additional treatments for 20 weeks post-JWK001 therapy, and showed considerable improvement in best-corrected visual acuity (BCVA). Professor Yang Yang, CEO and co-founder of Gene Vector Biotechnology, highlighted JWK001’s practicality, requiring only a single dose and showing promising safety and tolerance in early studies.

Gene Vector has developed six AAV gene therapy drugs, including JWK001, which have received ethical approvals and are currently undergoing Investigator Initiated Trials (IIT) at West China Hospital of Sichuan University, covering various medical areas like ophthalmology, genetic metabolism, and neuromuscular diseases.

PackGene Biotech provides analytical testing services for Gene Vector Biotech’s JWK001 IND pipeline, which expedites the clinical trial application process. These services encompass a range of activities including method development, validation, release testing, stability testing, and characterization studies. Committed to making gene therapy both accessible and affordable, PackGene Biotech continually advances its vector process and technology development. This dedication not only aids in drug innovation but also plays a significant role in expanding the application of gene therapy.

To learn more about PackGene’s AAV manufacture and AAV Analytical services, click here.
About PackGene

PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.

Related News

How to make mRNA therapeutics safe from the start

The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...

read more